BioPharma Credit backs $150M loan for CorMedix's Heron deal
What's the deal? CorMedixDealroom has a profile for this one. Try Dealroom → has secured a $150 million senior-secured loan facility to help fund its planned acquisition of Heron Therapeutics' commercial assets. The financing comes from BioPharma CreditDealroom has a profile for this one. Try Dealroom →, which commits up to $50 million, alongside $100 million from affiliated fund BioPharma Credit Investments V (Master) LP.
How it works: The facility splits into two $75 million tranches. CorMedix expects to draw the first to close the Heron deal — $145 million in cash plus 14,583,333 shares — with a second tranche available until June 30, 2028 for future acquisitions.
Why now? CorMedix announced the Heron purchase on November 9, 2026, a day before the loan agreement. The deal would add four marketed hospital- and clinic-administered drugs — Zynrelef, Aponvie, Cinvanti, and Sustol — to its commercial platform.
What's the endgame? CorMedix, a US biopharmaceutical company with a market capitalisation of roughly $418 million, sells products in institutional care settings. It expects pro forma 2026 revenue for the combined 12-product business of $465 million to $490 million once the acquisition closes, targeted for early 2027.
What could go wrong? The acquisition still needs regulatory clearance and Heron shareholder approval. It also adds leverage: the loan carries floating interest of three-month SOFR plus 5.75%, with a 3.5% SOFR floor, and matures five years after first funding.
The signal: The facility is financing for a strategic expansion rather than evidence of a broader equity-funding trend. For BioPharma Credit — London's only specialist life sciences debt investor — it extends a steady run of deals backing commercial-stage drug makers.
Read more: uk.advfn.com
Image credit: National Guard of the United States
